Categories: News

Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) — Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of New York Mellon as depositary, from 14 ordinary shares per ADS to 4000 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-285.714 reverse stock split of the ADSs.

The ADSs will continue to trade over-the-counter under a new CUSIP. Forward’s ordinary shares will not be affected by the change, the change will have no effect on the total number of ordinary shares in the ADS program, nor will it affect the total market value of our ADS or the market cap of the Company.

The new ADS to ordinary share ratio of 1-for-4000 will be effective on June 8, 2023.

No fractional ADSs will be issued. Holders who would otherwise receive fractional ADSs will receive a cash payment in lieu of such fractional ADSs. The cash in lieu rate will be set when the depositary sells the ADSs that would otherwise have been issued as fractional ADSs in one or more market trades.

Kindly see additional information at the links to the websites of the Company and its depositary, Bank of New York Mellon below.

Forward Pharma A/S Investor Relations Contact:
Investor Relations
investors@forward-pharma.com

Staff

Recent Posts

Genflow Biosciences PLC Announces Notification of Major Holdings

LONDON, UK / ACCESSWIRE / March 21, 2024 / TR-1: Standard form for notification of…

1 hour ago

Genflow Biosciences PLC Announces Publication of a Key European Patent

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION…

4 hours ago

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

First Patients Enrolled in Pivotal Study Evaluating AIMIGo™ System for Synthesizing a 12-Lead ECG Ongoing…

13 hours ago

Delivra Health Brands Announces Adoption of a New Fixed Share Option Plan

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - Delivra Health Brands Inc. (TSXV: DHB)…

13 hours ago

Avinger Reports Fourth Quarter and Full Year 2023 Results

New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens…

13 hours ago

Music’s Healing Influence on Our Physiology

Pioneering the Path of Sound Therapy with Biofield TuningBURLINGTON, VERMONT / ACCESSWIRE / March 20,…

16 hours ago